stem cells for diabetic chronic wounds healing
Phase 2
- Conditions
- diabetes mellitus.Diabetes mellitus due to underlying condition
- Registration Number
- IRCT20191007045008N2
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Sign Informed consent form
Diagnosed with diabetes mellitus
no pregnancy
grade 1 or 2 wounds
Men or women, 18 years old and above
Exclusion Criteria
uncontrolled disease history
pregnancy
cancerous or pre-cancerous lesions in the treated area
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of wound closure. Timepoint: several weeks to several months. Method of measurement: It will be measured using digital photography and software analysis.
- Secondary Outcome Measures
Name Time Method Time to complete wound closure. Timepoint: vary from weeks to months. Method of measurement: digital photography and software analysis.;Pain reduction. Timepoint: several weeks. Method of measurement: visual analog scale.;Quality of life improvement. Timepoint: several months to several years. Method of measurement: validated questionnaire.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the wound healing effects of human placenta-derived mesenchymal stem cells in diabetic patients?
How does a scaffold containing human placenta-derived mesenchymal stem cells compare to standard-of-care treatments for diabetic chronic wounds?
Which biomarkers are associated with successful healing outcomes in diabetic chronic wounds treated with stem cell scaffolds?
What are the potential adverse events of using human placenta-derived mesenchymal stem cells in diabetic wound healing and how can they be managed?
Are there any combination therapies or alternative stem cell sources that enhance the efficacy of placenta-derived mesenchymal stem cells for diabetic chronic wounds?